Screener
Eton Pharmaceuticals, Inc. ETON Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Eton Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Eton Pharmaceuticals, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001437749-26-017064
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | 67,095 | 65,960 |
| Commitments and contingencies (Note 13) | ||
| Stockholders’ equity | ||
| Common stock, $0.001 par value; 50,000,000 shares authorized; 27,359,791 and 27,047,061 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 27 | 27 |
| Additional paid-in capital | 141,528 | 138,621 |
| Accumulated deficit | (110,940) | (112,494) |
| Total stockholders’ equity | 30,615 | 26,154 |
| Total liabilities and stockholders’ equity | $97,710 | $92,114 |
Document
FAQ
- What is Eton Pharmaceuticals, Inc.'s total equity?
- Eton Pharmaceuticals, Inc. (ETON) reported total equity of $30.62M in Q1 2026.
- How has Eton Pharmaceuticals, Inc.'s total equity changed year-over-year?
- Eton Pharmaceuticals, Inc.'s total equity increased by 25.2% year-over-year, from $24.45M to $30.62M.
- What is the long-term trend for Eton Pharmaceuticals, Inc.'s total equity?
- Over 5 years (2020 to 2025), Eton Pharmaceuticals, Inc.'s total equity has grown at a 8.2% compound annual growth rate (CAGR), from $17.63M to $26.15M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Eton Pharmaceuticals, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude